Velphoro sucroferric oxyhydroxide regulatory update

The European Commission approved Velphoro sucroferric oxyhydroxide from Vifor-Fresenius Medical Care Renal Pharma Ltd. to control serum phosphorus levels in adults with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis. The company expects to launch the product in Germany and the U.K. “within the next few months,” but declined to disclose details or pricing information. The oral iron-based phosphate binder is marketed for the indication in the U.S. ...